Volume 4 Issue 1

Volume 3 Issue 1

Volume 2 Issue 1

Volume 1 Issue 1

Recent Articles

2020-02-27 Editorial

Autologous hematopoietic stem cell transplantation in systemic sclerosis patients


Systemic sclerosis (SScl) is an autoimmune disorder of unknown aetiology, characterised by fibrosis and microvascular injury of the affected organs. The hallmark of the disease is thickening and tightness of the skin and the subcutaneous tissue. SScl can affect virtually any organ systems, most importantly the skin, blood vessels, lungs, kidneys, gastrointestinal tract, and the heart [1].

Abstract Read Full Article HTML DOI: 10.29328/journal.jsctt.1001019 Cite this Article

2020-05-11 Review Article

Neutrophils, NETs, NETosis and their paradoxical roles in COVID-19


The pandemic of COVID-19 has adversely affected the world in many aspects. The health and economic sectors suffer most of the repercussions of this disease. The search for a cure for this rapidly spreading virus which is causing massive life losses worldwide requires clear understanding of the immunopathogenesis of this virus so as to develop pinpointed targeted therapies rather than relying mainly on supportive care measures and drug repurposing to fight this life-threatening virus infection.

Neutrophils, neutrophil extracellular traps (NETs), and NETosis are not well studied not only in COVID-19, but also in coroviruses in general. The review will shed lights on the functions of neutrophils, NETs, and NETosis in various infectious complications as well as in sepsis and acute lung conditions in an attempt to understand their actual roles and in order to help in designing targeted therapies in the near future.

Abstract Read Full Article HTML DOI: 10.29328/journal.jsctt.1001020 Cite this Article

2020-07-07 Review Article

The rising role of mesenchymal stem cells in the treatment of COVID-19 infections

Infectious diseases are a leading cause of death worldwide [1,2]. The Mid-20th century witnessed most of the antimicrobial discoveries but recently there is dramatic shortage of new classes of antimicrobial agents due to failure to build a sustainable antimicrobial discovery platform [1-4]. For example, antibiotics comprise ˂ 1.5% of the compounds under investigation at the major pharmaceutical and biotechnology companies [1,5].

Abstract Read Full Article HTML DOI: 10.29328/journal.jsctt.1001021 Cite this Article